Loading clinical trials...
Loading clinical trials...
This is an open-label, multicenter, phase 2 trial to explore the efficacy and safety of the combination of lenalidomide and R-CHOP for preventing the CNS relapse in the high-risk diffuse large B cell ...
Keep your clinical trial research organized — questions to ask, what to expect, and key details.
Lead Sponsor
Nanfang Hospital, Southern Medical University
NCT07523737 · Primary Central Nervous System Lymphoma (PCNSL), Diffuse Large B Cell Lymphoma (DLBCL)
NCT07260812 · Non-Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma (DLBCL)
NCT06451497 · Non Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma, and more
NCT05006716 · B-cell Malignancy, Marginal Zone Lymphoma, and more
NCT06026319 · Non-hodgkin Lymphoma, Relapsed Non-Hodgkin Lymphoma, and more
Nanfang hospital
Guangzhou, Guangdong
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions